Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eritoran - Eisai

Drug Profile

Eritoran - Eisai

Alternative Names: B-1287; E-5564; Eritoran tetrasodium

Latest Information Update: 13 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Class Disaccharides; Sugar phosphates
  • Mechanism of Action Endotoxin inhibitors; Lipid A inhibitors; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Immunological disorders
  • Discontinued Reperfusion injury; Septic shock

Most Recent Events

  • 06 Oct 2020 Eisai enters into a joint research agreement with KAN Research Institute, National Center for Global Health and Medicine, Nagasaki University, Yokohama City University to develop therapeutics to prevent COVID-2019 infections
  • 03 Aug 2020 Phase-III clinical trials in Immunological disorders (suppression of cytokine storm in patients with COVID-2019 infections) in USA (IV) before August 2020 (Eisai pipeline, August 2020)
  • 03 Jul 2020 Eisai in collaboration with University of Pittsburgh Medical Center and The Global Coalition for Adaptive Research plans the REMAP-COVID clinical trial for COVID-2019 infections (Monotherapy, Combination therapy) in US and Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top